BPC-157 and TB-500 stack (UK research notes): rationale, dosing conventions, caveats
The pairing of BPC-157 with thymosin beta-4 (TB-500) shows up constantly in UK research inboxes. The rationale rests on complementary preclinical mechanisms: BPC-157 accelerates angiogenesis and tenocyte activity locally; TB-500 promotes actin sequestration, cell migration, and myocardial/endothelial repair in rodent injury models (Malinda et al., 1999; Sosne et al., 2010).
Dosing conventions in the animal literature typically use BPC-157 at 10 µg/kg and TB-500 at ~2 mg twice weekly (rodent-equivalent scaling). Neither has completed randomised human trials for tendinopathy or soft-tissue injury. See the peptide stacking guide for full protocol references and the BPC-157 vs TB-500 comparison for mechanistic differences.
Neither peptide has MHRA marketing authorisation. Both are prohibited under WADA S0. UK supply is for laboratory research only.
More in Research News
Referenced supplier: PeptidesUK4U
Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
- HPLC-tested batches
- Batch-level CoAs
- UK cold-chain despatch
- 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
- 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
- 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.